Clinical and Experimental Pediatrics

The Korean Pediatric Society (대한소아청소년과학회)
권호 표지
DOI QR코드

DOI QR Code

Clinical and genetic characteristics of Gaucher disease according to phenotypic subgroups

  • Lee, Ju-Young (Department of Pediatrics, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine) ;
  • Lee, Beom-Hee (Department of Pediatrics, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine) ;
  • Kim, Gu-Hwan (Medical Genetics Center, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine) ;
  • Jung, Chang-Woo (Department of Pediatrics, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine) ;
  • Lee, Jin (Department of Pediatrics, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine) ;
  • Choi, Jin-Ho (Department of Pediatrics, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine) ;
  • Yoo, Han-Wook (Department of Pediatrics, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine)
  • Received : 2011.09.14
  • Accepted : 2011.11.17
  • Published : 2012.02.15
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: Gaucher disease is caused by a ${\beta}$-glucocerebrosidase (GBA) deficiency. The aim of this study is to investigate the clinical and genetic characteristics according to subtypes of Gaucher disease in the Korean population. Methods: Clinical findings at diagnosis, $GBA$ mutations, and clinical courses were reviewed in 20 patients diagnosed with Gaucher disease. Results: Eleven patients were diagnosed with non-neuronopathic type, 2 with acute neuronopathic type, and 7 with chronic neuronopathic type. Most patients presented with hepatosplenomegaly, thrombocytopenia, and short stature. In the neuronopathic group, variable neurological features, such as seizure, tremor, gaze palsy, and hypotonia, were noted at age $8.7{\pm}4.3$ years. B cell lymphoma, protein-losing enteropathy, and hydrops fetalis were the atypical manifestations. Biomarkers, including chitotriosidase, acid phosphatase, and angiotensin-converting enzyme, increased at the initial evaluation and subsequently decreased with enzyme replacement treatment (ERT). The clinical findings, including hepatosplenomegaly, thrombocytopenia, and skeletal findings, improved following ERT, except for the neurological manifestations. L444P was the most common mutation in our cohort. One novel mutation, R277C, was found. Conclusion: Although the clinical outcome for Gaucher disease improved remarkably following ERT, the outcome differed according to subtype. Considering the high proportion of the neuronopathic form in the Korean population, new therapeutic strategies targeting the central nervous system are needed, with the development of a new scoring system and biomarkers representing clinical courses in a more comprehensive manner.

Keywords

References

  1. Charles AS, Michael JB. Defects in metabolism of lipids. In: Kilegman RM, Behrman RE, Jenson HB, Stanton B, editors. Nelson textbook of pediatrics. 18th ed. Philadelphia: WB Saunders Co., 2007:595-7.
  2. Brady RO, Kanfer JN, Shapiro D. Metabolism of glucocerebrosides. II. Evidence of an enzymatic deficiency in Gaucher's disease. Biochem Biophys Res Commun 1965;18:221-5. https://doi.org/10.1016/0006-291X(65)90743-6
  3. Barneveld RA, Keijzer W, Tegelaers FP, Ginns EI, Geurts van Kessel A, Brady RO, et al. Assignment of the gene coding for human beta-glucocerebrosidase to the region q21-q31 of chromosome 1 using monoclonal antibodies. Hum Genet 1983;64:227-31. https://doi.org/10.1007/BF00279398
  4. Lam KW, Li CY, Yam LT, Smith RS, Hacker B. Comparison of prostatic and nonprostatic acid phosphatase. Ann N Y Acad Sci 1982;390:1-15. https://doi.org/10.1111/j.1749-6632.1982.tb40300.x
  5. Zimran A, Kay A, Gelbart T, Garver P, Thurston D, Saven A, et al. Gaucher disease. Clinical, laboratory, radiologic, and genetic features of 53 patients. Medicine (Baltimore) 1992;71:337-53. https://doi.org/10.1097/00005792-199211000-00002
  6. Cabrera-Salazar MA, O'Rourke E, Henderson N, Wessel H, Barranger JA. Correlation of surrogate markers of Gaucher disease. Implications for long-term follow up of enzyme replacement therapy. Clin Chim Acta 2004;344:101-7. https://doi.org/10.1016/j.cccn.2004.02.018
  7. Kundson AG, Kaplan WD. Genetics of the sphingolipidosis. In: Aronson SM, Volk BW, editors. Cerebral sphingolipidoses: a symposium on Tay- Sachs' disease and allied disorders. New York: Academic Press, 1962:395-411.
  8. Balicki D, Beutler E. Gaucher disease. Medicine (Baltimore) 1995;74:305- https://doi.org/10.1097/00005792-199511000-00002
  9. Barranger JA, Rice E, Sakallah SA, Sansieri C, Mifflin TE, Cooper DL. Enzymatic and molecular diagnosis of Gaucher disease. Clin Lab Med 1995;15:899-913.
  10. Jmoudiak M, Futerman AH. Gaucher disease: pathological mechanisms and modern management. Br J Haematol 2005;129:178-88. https://doi.org/10.1111/j.1365-2141.2004.05351.x
  11. Patterson MC, Horowitz M, Abel RB, Currie JN, Yu KT, Kaneski C, et al. Isolated horizontal supranuclear gaze palsy as a marker of severe systemic involvement in Gaucher's disease. Neurology 1993;43:1993-7. https://doi.org/10.1212/WNL.43.10.1993
  12. Horowitz M, Zimran A. Mutations causing Gaucher disease. Hum Mutat 1994;3:1-11. https://doi.org/10.1002/humu.1380030102
  13. Beutler E, Gelbart T. Hematologically important mutations: Gaucher disease. Blood Cells Mol Dis 1997;23:2-7. https://doi.org/10.1006/bcmd.1997.0114
  14. Jeong SY, Park SJ, Kim HJ. Clinical and genetic characteristics of Korean patients with Gaucher disease. Blood Cells Mol Dis 2011;46:11-4. https://doi.org/10.1016/j.bcmd.2010.07.010
  15. Choi HS, Kim SH, Ida H, Kim HJ. The clinical characteristics and gene analysis of Korean Gaucher disease with central nervous system involvement. J Korean Pediatr Soc 2000;43:611-8.
  16. Martins AM, Valadares ER, Porta G, Coelho J, Semionato Filho J, Pianovski MA, et al. Recommendations on diagnosis, treatment, and monitoring for Gaucher disease. J Pediatr 2009;155(4 Suppl):S10-8. https://doi.org/10.1016/j.jpeds.2009.07.004
  17. Starzyk K, Richards S, Yee J, Smith SE, Kingma W. The long-term international safety experience of imiglucerase therapy for Gaucher disease. Mol Genet Metab 2007;90:157-63. https://doi.org/10.1016/j.ymgme.2006.09.003
  18. Chen M, Wang J. Gaucher disease: review of the literature. Arch Pathol Lab Med 2008;132:851-3.
  19. Grigorescu Sido P, Drugan C, Cret V, Al-Kzouz C, Denes C, Coldea C, et al. Outcome of enzyme replacement therapy in patients with Gaucher disease type I. The Romanian experience. J Inherit Metab Dis 2007;30: 783-9. https://doi.org/10.1007/s10545-007-0621-z
  20. vom Dahl S, Mengel E. Lysosomal storage diseases as differential diagnosis of hepatosplenomegaly. Best Pract Res Clin Gastroenterol 2010;24:619-28. https://doi.org/10.1016/j.bpg.2010.09.001
  21. Hollak CE, van Weely S, van Oers MH, Aerts JM. Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease. J Clin Invest 1994;93:1288-92. https://doi.org/10.1172/JCI117084
  22. Grace ME, Balwani M, Nazarenko I, Prakash-Cheng A, Desnick RJ. Type 1 Gaucher disease: null and hypomorphic novel chitotriosidase mutations-implications for diagnosis and therapeutic monitoring. Hum Mutat 2007;28:866-73. https://doi.org/10.1002/humu.20524
  23. Dodelson de Kremer R, Paschini de Capra A, Angaroni CJ, Giner de Ayala A. Plasma chitotriosidase activity in Argentinian patients with Gaucher disease, various lysosomal diseases and other inherited metabolic disorders. Medicina (B Aires) 1997;57:677-84.

Cited by

  1. Gaucher Disease and Its Treatment Options vol.47, pp.9, 2013, https://doi.org/10.1177/1060028013500469
  2. Allele frequency of a 24 bp duplication in exon 10 of the CHIT1 gene in the general Korean population and in Korean patients with Gaucher disease vol.59, pp.5, 2014, https://doi.org/10.1038/jhg.2014.16
  3. Eliglustat tartrate for the treatment of adults with type 1 Gaucher disease vol.9, pp.None, 2015, https://doi.org/10.2147/dddt.s77760
  4. Allelic Frequency of a 24-bp Duplication in Exon 10 of the CHIT1 Gene in the General Iranian Population vol.20, pp.1, 2012, https://doi.org/10.1089/gtmb.2015.0116
  5. A Novel Functional Missense Mutation p.T219A in Type 1 Gaucher's Disease vol.129, pp.9, 2016, https://doi.org/10.4103/0366-6999.180523
  6. Substrate reduction therapy in three patients with Gaucher disease vol.13, pp.2, 2016, https://doi.org/10.5734/jgm.2016.13.2.72
  7. Neuronopathic Gaucher disease presenting with microcytic hypochromic anemia vol.109, pp.3, 2012, https://doi.org/10.1007/s12185-018-2559-3
  8. Neurological effects of glucocerebrosidase gene mutations vol.26, pp.3, 2012, https://doi.org/10.1111/ene.13837
  9. Ophthalmic manifestations of Gaucher disease: the most common lysosomal storage disorder vol.103, pp.3, 2019, https://doi.org/10.1136/bjophthalmol-2018-312846
  10. Long-Term Clinical Course of a Korean Patient with Chronic Neuropathic (type III) Gaucher Disease vol.1, pp.2, 2012, https://doi.org/10.22742/jig.2019.1.2.15
  11. Clinical and Genetic Varieties of Gaucher Disease in Iraqi Children vol.10, pp.1, 2020, https://doi.org/10.1055/s-0040-1720956
  12. The GBA p.G85E mutation in Korean patients with non-neuronopathic Gaucher disease: founder and neuroprotective effects vol.15, pp.None, 2012, https://doi.org/10.1186/s13023-020-01597-0
  13. The remote assessment of parkinsonism supporting the ongoing development of interventions in Gaucher disease vol.11, pp.6, 2021, https://doi.org/10.2217/nmt-2021-0032